Found 4355 articles for: ""
INDIVIDUAL ARTICLE: An Algorithm for the Management of Atopic Dermatitis in People With Skin of Color
August 2023 | Volume 22 | Issue 8 | Supplement Individual Articles | SF386361s3 | Copyright © August 2023
Background: Variations in the epidemiology, clinical presentation, and disease course in skin of color (SOC) atopic dermatitis (AD) patients have been reported that may impact tr...
Read MoreEXTRA, EXTRA, Treatment Approaches for EXTRAmammary Paget Disease
August 2023 | Volume 22 | Issue 8 | Features | 844 | Copyright © August 2023
Desai S, McCormick E, Nelson K, et al. EXTRA, EXTRA, treatment approaches for EXTRAmammary Paget disease. J Drugs Dermatol. 2023;22(8):844-845. doi:10.36849/JDD.2023.NVRN0823...
Read MoreINDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment
August 2023 | Volume 22 | Issue 8 | Supplement Individual Articles | SF381621s5 | Copyright © August 2023
Most patients with plaque psoriasis exhibit mild-to-moderate disease and topical therapies remain the mainstay treatment option for these patients. The use of topical steroids in combination with...
Read MoreDermatology in Contemporary Times: Building Awareness of Social Media's Association With Adolescent Skin Disease and Mental Health
August 2023 | Volume 22 | Issue 8 | Original Article | 817 | Copyright © August 2023
Background: The contribution of psychological disorders to the burden of skin disease has been poorly explored in adolescent patients. The review aims to provide insights into the psychological, socia...
Read MoreLong-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
August 2023 | Volume 22 | Issue 8 | Original Article | 810 | Copyright © August 2023
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged ≥ 12 years based on results from two 12-week Phase 3 studies in patients with...
Read MoreDiagnosis and Management of Pediatric Psoriasis: An Overview for Pediatricians
August 2023 | Volume 22 | Issue 8 | Original Article | 742 | Copyright © August 2023
Pediatric psoriasis (PsO) and its associated comorbidities carry physical and psychosocial burdens in children and adolescents, which can negatively impact quality of life. However, features dist...
Read MoreConsensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 736 | Copyright © August 2023
This article aims to provide consensus statements on the use of corticosteroid-containing topical medications for the management of psoriasis. This Psoriasis Expert Group (PEG) includes dermatolo...
Read MorePsoriasis and Skin Barrier Dysfunction: The Role of Gentle Cleansers and Moisturizers in Treating Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 773 | Copyright © August 2023
Background: Psoriasis is a chronic immune-mediated dermatologic disorder with multisystemic comorbidities, which is effectively treated with a range of prescription therapies. St...
Read MoreTildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 766 | Copyright © August 2023
Background: This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients.Read More The Patient-Physician Relationship and Adherence: Observations From a Clinical Study
August 2023 | Volume 22 | Issue 8 | Editorials | 838 | Copyright © August 2023
Improved patient-physician relationships (PPR) are associated with better patient satisfaction and disease outcomes, however, there is limited literature assessing how PPR affects adherence in de...
Read MoreAntimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study
August 2023 | Volume 22 | Issue 8 | Editorials | 840 | Copyright © August 2023
The early phase of the COVID-19 pandemic prompted a repurposing of antiviral and immunomodulatory drugs as investigational therapeutics, including hydroxychloroquine and chloroquine. While antima...
Read MoreRethinking the Inflammatory Balance in Psoriasis and Atherosclerosis
August 2023 | Volume 22 | Issue 8 | Features | 832 | Copyright © August 2023
Guénin S, Kazemi A, Cline A, et al. Rethinking the inflammatory balance in psoriasis and atherosclerosis. J Drugs Dermatol. 2023;22(8):832-833. doi:10.36849/JDD.7082...
Read MoreA Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults
August 2023 | Volume 22 | Issue 8 | Original Article | 761 | Copyright © August 2023
Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque ...
Read MoreReal-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study
August 2023 | Volume 22 | Issue 8 | Original Article | 754 | Copyright © August 2023
Background: Tildrakizumab is an anti–interleukin-23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. This analysis eva...
Read MoreReview of Superficial Cryotherapy for the Treatment of Alopecia Areata
August 2023 | Volume 22 | Issue 8 | Original Article | 802 | Copyright © August 2023
Cryotherapy has recently been examined as a potential treatment for alopecia areata (AA). AA is classically managed with intralesional or systemic steroids but relapse rates among those with long...
Read MoreHormonal Treatments in Hidradenitis Suppurativa: A Systematic Review
August 2023 | Volume 22 | Issue 8 | Original Article | 785 | Copyright © August 2023
Background: Hidradenitis suppurativa (HS) is an inflammatory skin condition characterized by recurrent abscesses, nodules, and sinus tracts. Hormones are thought to play an impor...
Read MoreTapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 779 | Copyright © August 2023
Topical treatments remain the foundation of psoriasis management. Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a first-in-class, non-steroidal, topical, aryl hydrocarbon receptor (AhR) ago...
Read MoreJuvenile Pemphigus Foliaceus in a Patient With Psoriasis Receiving Narrow-Band Ultraviolet-B: Successful Treatment With Rituximab
August 2023 | Volume 22 | Issue 8 | Case Reports | 830 | Copyright © August 2023
Pemphigus foliaceus is an autoimmune blistering disease of the skin that is not frequently associated with mucous membrane involvement. It is characterized by immunoglobulin G (IgG) antibodies ag...
Read MoreTalquetamab-Induced Grover's Disease
August 2023 | Volume 22 | Issue 8 | Case Reports | 828 | Copyright © August 2023
Kresch M, Guénin S, Mubasher A, et al. Talquetamab-induced Grover’s disease. J Drugs Dermatol. 2023;22(8):828-829. doi:10.36849/JDD.7170...
Read MoreVerrucous Psoriasis: Rare Variant and Novel Treatment
August 2023 | Volume 22 | Issue 8 | Case Reports | 826 | Copyright © August 2023
Xenopoulou D, Pochat C, Greco E. Verrucous psoriasis: rare variant and novel treatment. J Drugs Dermatol. 2023;22(8):826-827. doi:10.36849/JDD.C6874R1...
Read MoreMedia and other results for: ""